119th Congress · introduced in the Senate · Feb 25, 2025
Innovation in Pediatric Drugs Act of 2025
Official title from Congress.gov
Latest action (Feb 25, 2025): Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (Feb 25, 2025)
Innovation in Pediatric Drugs Act of 2025
This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to require pediatric studies on certain orphan drugs and to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements.
Specifically, the bill would impose pediatric study requirements on drugs for rare diseases or conditions (i.e., orphan drugs) if the FDA determines that (1) the drug could improve the treatment, diagnosis, or prevention of a disease compared with currently available products for the relevant pediatric population; or (2) there is a need for additional options within the drug’s class or indication. (Under current law, pediatric study requirements generally do not apply to orphan drugs.) The FDA must issue guidance describing how these changes will be implemented, including information on how waivers will be granted.
The bill also permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirements.
Additionally, the bill authorizes the National Institutes of Health to allot a certain amount of funds for priority pediatric research, including research on drugs with no remaining patents on which pediatric studies are needed.
Finally, the Government Accountability Office must report on the bill’s impact on rare disease drug development and on the availability of pediatric information on orphan drugs.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)
Introduced in Senate
Actions from Congress.gov, newest first.
Cancer · Child health · Congressional oversight · Drug safety, medical device, and laboratory regulation · Drug therapy · Government information and archives · Government studies and investigations · Medical research · Prescription drugs · Research administration and funding
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
35 citations; showing the 25 most recently posted.
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
…e Transparency Act of 2026 H.R. 10280, 9-8-8 Implementation Act of 2026 S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…ons by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHILDREN'S CAUSE FOR CANCER · lobbying firm or registrant: I STREET ADVOCATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 6, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
S. 705, The Innovation in Pediatric Drugs Act; Medicaid coverage for pediatric cancer, HR 8839, The Lainie Jones Comprehensive Cancer Survivorship Act; S.4717, The As…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 22, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
…29, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$2,360,000
Spent on own lobbying
…acid synthesis security and biotechnology governance ---Most Favored Nation Drug Pricing Proposals Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…ons by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHILDREN'S CAUSE FOR CANCER · lobbying firm or registrant: I STREET ADVOCATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 9, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer, HR 8839, The Lainie Jones Comprehensive Cance…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 24, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
…29, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$1,620,000
Spent on own lobbying
…g Proposals Opioid Crisis ---Coverage and Reimbursement ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 15, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…ons by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHILDREN'S CAUSE FOR CANCER · lobbying firm or registrant: I STREET ADVOCATES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 15, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 23, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
…Whole Milk for Healthy Kids Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 1261, Creating Opp…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$1,510,000
Spent on own lobbying
…Nation Pricing Opioid Crisis ---SUPPORT Act Orphan Drug Issues ---H.R.946/S.1862: ORPHAN Cures Act ---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act ---Implementation of the I…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
…ons by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GLAXOSMITHKLINE LLC · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 12, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b) program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GLAXOSMITHKLINE LLC · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 12, 2026 · issue area: Pharmacy
$50,000
Paid to lobbying firm
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHILDREN'S CAUSE FOR CANCER · lobbying firm or registrant: I STREET ADVOCATES
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 8, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 22, 2025 · issue area: Health Issues
$24,000
Paid to lobbying firm
…826, 988 LGBTQ+ Youth Access Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 1261, Creating Opportunities…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GLAXOSMITHKLINE LLC · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$40,000
Paid to lobbying firm
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GLAXOSMITHKLINE LLC · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Pharmacy
$40,000
Paid to lobbying firm
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHILDREN'S CAUSE FOR CANCER · lobbying firm or registrant: I STREET ADVOCATES
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$10,000
Paid to lobbying firm
S. 705, The Innovation in Pediatric Drugs Act; survivorship in pediatric cancer, Medicaid coverage for pediatric cancer
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$110,000
Spent on own lobbying
…ons by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS · lobbying firm or registrant: MASON CONSULTING, LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 23, 2025 · issue area: Health Issues
$24,000
Paid to lobbying firm
…observed from May 6 through May 12, 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836, Children and Teens Online Privacy Protection Act S. 891, Bipartisan Health Care Act S. 931/H.R. 2509, Connecting Ou…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 17, 2025 · issue area: Health Issues
$650,000
Spent on own lobbying
…program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for ped…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GLAXOSMITHKLINE LLC · lobbying firm or registrant: LMH STRATEGIC SOLUTIONS
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$40,000
Paid to lobbying firm
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing